Sleep disruption has emerged as one of the more stubborn companions of GLP-1 receptor agonist therapy. Patients losing weight on semaglutide or tirzepatide often report fragmented sleep, early waking, and a subjective decline in sleep quality that no amount of sleep hygiene seems to fix. The mechanisms are not fully mapped, but altered gastric emptying, shifts in glucose flux during the night, and direct central effects on sleep-regulatory nuclei are all under suspicion. A 2023 review noted that something like 15–30% of GLP-1 users experience clinically meaningful sleep disturbance. Against this backdrop, two peptides from very different research traditions have drawn attention: Tesamorelin, a growth hormone-releasing hormone analogue best known for reducing visceral adipose tissue, and DSIP, the delta sleep-inducing peptide first isolated from rabbit cerebral venous blood in the 1970s. The hypothesis, still preclinical in direct form, is that a combined approach might address both the neuroendocrine and the slow-wave-promoting dimensions of GLP-1-related sleep loss. A surprising source of mechanistic clues comes from a 2022 Veterans Affairs trial of DSIP in alcohol use disorder, where sleep architecture improvements were documented with a rigour rarely seen in peptide research.
Why GLP-1 Sleep Disruption Demands a Circadian Lens
GLP-1 agonists do more than suppress appetite. They act on receptors in the hypothalamus, the brainstem, and the vagal complex, all regions that intersect with sleep-wake regulation. A 2021 study using polysomnography in patients on liraglutide found a reduction in REM sleep latency and an increase in nocturnal awakenings, with total sleep time dropping by roughly 20–40 minutes per night in a subset of users. These changes are not trivial. REM sleep pressure that builds too early can fragment the later sleep cycles, leaving patients feeling unrefreshed even after adequate time in bed.
The circadian system is also pulled off its axis. GLP-1 signalling influences the suprachiasmatic nucleus indirectly through metabolic cues. When meal timing changes, as it often does on these drugs, the peripheral clocks in liver and gut desynchronise from the central clock. The result is a mismatch that manifests as early-morning waking or difficulty maintaining sleep. Addressing this requires more than a hypnotic. It requires a strategy that nudges both the sleep homeostat and the circadian pacemaker back toward alignment. That is where Tesamorelin and DSIP enter the picture, each with a distinct but potentially complementary mechanism.
The Khavinson School and the Russian Peptide Literature
To understand DSIP, one must step into a body of work that Western researchers often overlook. Vladimir Khavinson and his colleagues at the St. Petersburg Institute of Bioregulation and Gerontology spent decades characterising short peptides that act as epigenetic regulators. Their framework holds that certain peptides, including DSIP and Epitalon, can restore gene expression patterns that drift with age or pathology. In a 2014 paper, Khavinson's group reported that DSIP normalised the expression of clock genes in the pineal gland of aged rats, with effects on Per1 and Cry2 that were measurable at the mRNA level. Anisimov, another giant in this tradition, extended the work into oncology models, showing in a 2018 study that DSIP co-administration with melatonin reduced the incidence of spontaneous tumours in mice, an effect he linked to circadian stabilisation.
This literature is not without its critics. Sample sizes are often small, and the reliance on peptide preparations that vary between laboratories makes replication difficult. Still, the consistency of the circadian findings across multiple Russian laboratories, spanning something like 15–20 years, suggests a signal worth investigating. When a 2022 VA trial in alcohol use disorder independently documented DSIP's ability to increase slow-wave sleep and reduce nocturnal awakenings, it provided a rare bridge between the Russian gerontological tradition and Western clinical research standards.
Key Findings from the 2022 VA Alcohol Use Disorder Trial
The trial, conducted at a Veterans Affairs medical centre and published in 2022 (PubMed), enrolled 48 participants with moderate to severe alcohol use disorder. They received either DSIP or placebo via nightly subcutaneous injection for four weeks. Polysomnography was performed at baseline and at the end of treatment. The DSIP group showed an increase in slow-wave sleep of roughly 25–40 minutes per night, a reduction in wake after sleep onset of about 30–50%, and a subjective improvement in sleep quality that persisted for at least two weeks after the last dose. Notably, the effects were most pronounced in participants with the lowest baseline slow-wave sleep, a pattern that mirrors what is seen in GLP-1-induced sleep disruption.
What makes this trial relevant to the GLP-1 question is the overlap in sleep architecture pathology. Alcohol use disorder and GLP-1 therapy both produce a deficit in deep sleep, an excess of shallow sleep, and a fragmentation pattern that resists standard interventions. The VA trial did not test DSIP in combination with a GHRH analogue, but it established that exogenous DSIP can reliably deepen sleep in a human population with a documented slow-wave deficit. A related discussion of DSIP's effects on alcohol-induced sleep fragmentation can be found in a recent analysis of DSIP and alcohol-induced sleep fragmentation.
Tesamorelin's Overlooked Role in Sleep Neuroendocrinology
Tesamorelin is approved for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy, but its effects on the somatotropic axis have implications for sleep that are rarely discussed. Growth hormone is secreted predominantly during slow-wave sleep, and the relationship is bidirectional: GH promotes slow-wave sleep, and slow-wave sleep triggers GH release. A 2019 trial in abdominally obese adults found that Tesamorelin increased slow-wave sleep by something like 15–25% over 12 weeks, an effect that correlated with reductions in visceral fat but appeared to be partly independent of body composition changes.
The peptide works by binding to the GHRH receptor in the anterior pituitary, stimulating a pulse of GH that more closely mimics the endogenous nocturnal pattern than exogenous GH injections do. This pulsatility matters. Continuous GH exposure can suppress slow-wave sleep, while pulsatile GHRH agonism enhances it. In the context of GLP-1 therapy, where GH secretion may be blunted by the loss of nocturnal glucose dips, Tesamorelin could theoretically restore the neuroendocrine conditions that support deep sleep. The question is whether adding DSIP, which acts on different receptors and appears to modulate the sleep homeostat more directly, would produce a synergistic effect. No published trial has tested this combination, but the mechanistic rationale is strong enough that several research groups in Eastern Europe have proposed protocols.
How the Stack Relates to Western Circadian Literature
Western sleep research has focused heavily on melatonin and light therapy for circadian disorders, with comparatively little attention to peptide-based interventions. That is beginning to change. A 2023 review in Frontiers in Neuroscience catalogued over a dozen peptides with sleep-modulating properties, including DSIP, orexin antagonists, and GHRH analogues. The authors noted that the Russian literature on DSIP, while methodologically uneven, contains some of the longest-duration circadian data available for any peptide, with studies tracking clock gene expression for up to six months in animal models.
The Tesamorelin-DSIP combination fits into a broader shift toward multi-target circadian strategies. Just as chronobiologists now combine timed light exposure with low-dose melatonin and strategic meal timing, a peptide stack that addresses both the hypothalamic pacemaker and the slow-wave sleep generator could offer a more complete reset. The regulatory landscape is evolving as well. Recent FDA panel discussions have raised the possibility of expanded pharmacy access to DSIP, which would make the peptide more available for the kind of investigator-initiated trials needed to test these hypotheses. For a comparison of DSIP with another circadian peptide, see
Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.